Dtsch Med Wochenschr 2017; 142(18): 1348-1356
DOI: 10.1055/s-0042-111609
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Organinteraktionen: Herz und Niere

Organ Interactions: Heart and kidney
Daniel Salleck
,
Stefan John
Further Information

Publication History

Publication Date:
08 September 2017 (online)

Abstract

The interactions between heart and kidney are various and of clinical relevance. Worsening of one organ often influences the function of the other. With NYHA and KDIGO we have classification systems for heart and kidney failure and those should be used for cardiorenal systems as well. Furthermore there is a useful classification system for cardiorenal syndromes itself. Cardiorenal syndrome is a complex illness which should be treated by interdisciplinary medical teams. A key roll in pathophysiology is the renin-angiotensin-aldosteron-system (RAAS). It's activation is followed by an increased salt and water retention as well as increased systemic an renal vasoconstriction leading to hypervolaemia an left ventricular hyperthrophy. General recommendations for the prevention of cardiovascular disease are good for the prevention of cardiorenal syndromes as well. RAAS-blockers should be used to stop cardial remodelling. A good regulation of hypertension and diabetes is important. Most important is a balanced intravasal volume. With volume overload negative balances can improve renal perfusion and therefor renal function. The furosemide stress test is a good cinical tool to check wether there is appropriate urine excretion and if volume overload can be treated by loop diuretics. Preload reduction can reduce cardiac output ahd renal function can be worsened especially in the beginning of overload-reduction. This may be acceptable.

Herz und Niere wirken auf vielfältige Weise aufeinander ein: Die Verschlechterung einer Organfunktion kann eine Verschlechterung der jeweils anderen befördern. Das komplexe Krankheitsbild bedarf eines interdisziplinären Behandlungsansatzes. Ziel dieses Beitrags ist es, eine Übersicht über die klinisch relevanten Interaktionen zwischen Herz und Niere sowie über aktuelle Therapieoptionen zu bieten.

 
  • Literatur

  • 1 Ronco C, Haapio M, House AA. et al. Cardiorenal Syndrome. J Am Coll Cardiol 2008; 52: 1527-1539
  • 2 Hatamizadeh P, Fonarow GC, Budoff MJ. et al. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 2013; 9: 99-111
  • 3 Janssens U, Joannidis M. Cardiorenal Syndromes. Med Klin Intensivmed Notfmed 2016; 111: 341-358 Epub 2016 May 10. German
  • 4 John S, Willam C. Lung and kidney failure. Pathogenesis, interactions, and therapy. Med Klin Intensivmed Notfmed 2015; 110: 452-458
  • 5 Heywood JT, Fonarow GC, Costanzo MR. et al. High prevalence of renal dysfunction and its impact on outcome in 118 465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422-430
  • 6 Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
  • 7 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 3: S1-S150 Im Internet: http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf
  • 8 Collins AJ, Li S, Gilbertson DT. et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003; 87: 24-31
  • 9 Hoppe UC, Böhm M, Dietz R. et al. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 2005; 94: 488-509 Im Internet: http://leitlinien.dgk.org/files/2005_Leitlinie_Therapie_Chronische_Herzinsuffizienz.pdf
  • 10 KDIGO AKI Working Group (2012). KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 3: 1-150
  • 11 Yoshitsugu O, Taehee K, Csaba PK. et al. Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome. Cardiorenal Med 2016; 6: 83-98
  • 12 Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. J Am Coll Cardiol 2006; 47: 1-8 Epub 2005 Dec 15
  • 13 Damman K, Tang WH, Felker GM. et al. Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. J Am Coll Cardiol 2014; 63: 853-871
  • 14 Nohria A, Hasselblad V, Stebbins A. et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51 (13) 1268-1274
  • 15 Lameire N, Verbeke M, Vanholder R. Prevention of clinical acute tubular necrosis with drug therapy. Nephrol Dial Transplant 1995; 11: 1992-2000
  • 16 Vanholder R, Sever MS, Erek E. et al. Rhabdomyolysis. J Am Soc Nephrol 2000; 11: 1553-1561
  • 17 Zander J, Döbbeler G, Nagel D. et al. Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study. Crit Care 2016; 20: 79
  • 18 Solomon R, Werner C, Mann D. et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-1420
  • 19 Costanzo MR, Guglin ME, Saltzberg MT. et al. (UNLOAD Trial Investigators). Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-683
  • 20 Kwok CS, Wong CW, Rushton CA. et al. Ultrafiltration for acute decompensated cardiac failure: A systematic review and meta-analysis. Int J Cardiol 2017; 228: 122-128
  • 21 Schwenger V, Remppis BA, Westenfeld R. et al. Dialyse- und Ultrafiltrationsverfahren bei kardiorenalem Syndrom. Empfehlung der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz und Kreislaufforschung e. V. und der Deutschen Gesellschaft für Nephrologie e.V. Dtsch Med Wochenschr 2014; 139: e1-e8
  • 22 Werdan K, Ruß M, Buerke M. German Cardiac Society; German Society of Intensive Care and Emergency Medicine; German Society for Thoracic and Cardiovascular Surgery; (Austrian Society of Internal and General Intensive Care Medicine; German Interdisciplinary Association of Intensive Care and Emergency Medicine; Austrian Society of Cardiology; German Society of Anaesthesiology and Intensive Care Medicine; German Society of Preventive Medicine and Rehabilitation. et al. Deutsch-österreichische S3-Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie“. Kardiologe 2011; 5: 166-224
  • 23 Klein SJ, Joannidis M. Renal replacement therapy in acute kidney injury. Med Klin Intensivmed Notfmed 2017; 112: 437-443
  • 24 Chvojka J, Sykora R, Krouzecky A. et al. Renal haemodynamic, microcirculatory, metabolic and histopathological responses to peritonitis-induced septic shock in pigs. Crit Care 2008; 12: R164
  • 25 Testani JM, Chen J, McCauley BD. et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265-272
  • 26 Chawla LS, Davison DL, Brasha-Mitchell E. et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 2013; 17: R207
  • 27 Matsue Y, Suzuki M, Nagahori W. et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovasc Drugs Ther 2014; 28: 73-77
  • 28 Wali RK, Wang GS, Gottlieb SS. et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005; 45: 1051-1060